Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 18/20 | 0.86 |
| ▸ | THRB | P10828 | 18/20 | 0.86 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.80 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | ASPH | Q12797 | 1/20 | 0.78 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.78 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27433210 | 0.92 | THRB (1.00) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL27434293 | 0.92 | THRB (1.00) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL27433213 | 0.91 | THRB (1.00) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL27433220 | 0.91 | THRB (1.00) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL27433214 | 0.90 | THRA (0.80) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL523407 | 0.89 | THRA (0.69) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL28422434 | 0.89 | THRA (0.79) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL27433227 | 0.89 | THRB (0.96) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL27433234 | 0.89 | THRA (1.00) | THRATHRBEGLN1BBOX1SLC6A2 | |
| SCHEMBL22168443 | 0.89 | THRA (0.80) | THRATHRBEGLN1BBOX1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919463-B9 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2011-02-02 | — | — | EP | claimed |
| EP-1919463-B1 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2010-06-09 | — | — | EP | claimed |
| US-8530404-B2 | Compounds and methods for treatment of cancer | FIBROGEN, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| EP-1919463-B9 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20110015223-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100204269-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | FIBROGEN, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| EP-1919463-B1 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2010-06-09 | — | — | EP | disclosed |
| US-7713986-B2 | administering an enzyme inhibitor for inhibiting hypoxia inducible factor (HIF) hydroxylase activity; who is refractory to or is at risk for being refractory to recombinant human EPO therapy | FIBROGEN, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1919463-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007146425-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070292433-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070004627-A1 | Compounds and methods for treatment of cancer | FIBROGEN, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204269-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | EPOR, MCL1, HIF1AN | THRA 1532/4885THRB 1848/4885EGLN1 25/4885 |
| US-20110015223-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | THRA 613/4885THRB 1146/4885EGLN1 21/4885 |
| US-20070004627-A1 | Compounds and methods for treatment of cancer | TP53, MKI67, HDGF | THRA 4087/4885THRB 3302/4885EGLN1 98/4885 |
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | THRA 613/4885THRB 1146/4885EGLN1 21/4885 |
| US-20070292433-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | EPOR, MCL1, HIF1AN | THRA 1532/4885THRB 1848/4885EGLN1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.